Tag: acorda therapeutics

Pharma Outlook 2019: Drug Pricing Dialogue Continues

During this challenging time in healthcare news, our pharma outlook aims to help investors steer through the industry.

Acorda Provides Financial and Pipeline Update for Third Quarter 2018

Acorda Therapeutics (Nasdaq:ACOR) provided a financial and pipeline update for the third quarter ended September 30, 2018. As quoted in...

Biotech Executives on Trump’s Immigration Ban

Donald Trump's immigration ban has sparked outrage around the world, and biotech executives are speaking out.

What Will Trump's Presidency Mean for Pharma Stocks?

With January fast approaching, it’s worthwhile to reexamine Trump’s stance on various industry-related questions.

Acorda Discontinues Dalfampridine for Treatment of Post-Stroke Mobility Issues

Acorda Therapeutics has announced that results from its MILESTONE clinical study did not support continued development of dalfampridine as a...

Biotie Therapies Corp. Announces That the Delisting of Its American Depositary Shares from NASDAQ Global Select Market Has Become Effective

TURKU, Finland–(BUSINESS WIRE)–Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V) (“Biotie” or the “Company”) announces that the voluntary delisting of its American...

Biotie Therapies Corp. to Delist Its American Depositary Shares from the Nasdaq Global Select Market

TURKU, Finland–(BUSINESS WIRE)–Biotie Therapies Corp. (“Biotie”) today announces that its Board of Directors has resolved to voluntarily delist its American...